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Field testing a protocol to 
facilitate the involvement of 
pharmacists in community 
based palliative care 
Abstract
Background
Most palliative care patients and their 
carers will interact with a pharmacist, 
particularly when obtaining medication 
during their illness. Pharmacists working 
in the community do not have a formal 
role in the care of patients who are 
receiving palliative care. 
Objective
The aim of this study was to field test a 
protocol to coordinate a formal medication 
management review of palliative care 
patients by an accredited pharmacist.
Methods
Eligible patients resident in the 
community were recruited by a palliative 
care nurse. Patients consented to a 
formal review of their medication by an 
accredited pharmacist. The request for 
the review was endorsed by the patient’s 
doctor. One accredited pharmacist, from a 
list of 18 accredited pharmacists who had 
attended a short course on palliative care 
and who had access to an experienced 
palliative care pharmacist, reviewed the 
medication at the patient’s residence. 
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The pharmacist then reported their 
recommendations to a project manager 
who passed them back to the doctor. 
Patients and relatives were able to consult 
the pharmacist if they required further 
help for a number of weeks post-review.
Results
Forty patients and 13 pharmacists 
participated over a four month period. 
Between two and 30 days elapsed from 
patient consent to the pharmacist’s report 
to the referring doctor (M = 10.6 days, 
SD = 6.0). Thirteen pharmacists conducted 
0–9 reviews each and made 145 
recommendations. Only three pharmacists 
recorded post-review patient interactions 
in diaries. Out of all interactions that took 
place between these three pharmacists 
and corresponding patients, almost half 
were initiated by the pharmacist. These 
were used mainly to share or request 
information, although two resulted in 
medication changes. Experts in palliative 
care and the patients were generally 
very positive about the results of the 
medication review.
Conclusions 
An innovation that builds on the existing 
system for Medication Management 
Review to engage with patients in 
palliative care is valuable. This project was 
an important first step in developing a 
suitable protocol. In this case the protocol 
was only partially successful although the 
project contributes to existing knowledge 
and understanding in this area.
Background 
Palliative care is defined as: 
An approach that improves the quality of 
life of patients and their families facing the 
problem associated with life-threatening 
illness, through the prevention and relief of 
suffering by means of early identification 
and impeccable assessment and treatment 
of pain and other problems, physical, 
psychosocial and spiritual.1 
As the focus of palliative care is on the 
alleviation of symptoms, most patients 
will be taking prescribed medicines 
to manage these symptoms.2 As such, 
the community pharmacist is likely 
to encounter palliative care patients 
and their carers and to be providing 
medication to patients receiving home-
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based palliative care, particularly as many 
palliative care patients have complex 
medication regimens, involving off-label 
or off-license prescribing that increases 
their risk for drug-related problems.3 
Despite this regular contact with palliative 
care patients and their carers, community 
pharmacists are rarely active members of 
community-based palliative health care 
teams. Yet the community pharmacist’s 
potential contribution is clear. It includes 
providing information regarding the 
management of medications and 
their effective use; support for self-
managed care and disease specific 
care management information; patient 
assessments; systematic medication 
reviews; and patient counselling.4,5 One 
way of providing this input is the use 
of medication management reviews by 
trained, accredited pharmacists serving 
palliative care patients in the community.
Currently in Australia ‘accredited’ 
pharmacists can claim a fee for conducting 
a review of a patient’s medication and can 
make recommendations on the receipt of 
a formal signed referral from the patient’s 
doctor.6 However, for such reviews to 
be conducted routinely, the process of 
ordering and conducting a review must 
be practical and adequately rewarded for 
the required time commitment.7 This study 
examined a protocol to formally invite the 
pharmacist to be involved in the palliative 
care team to conduct a medication 
management review, focusing on their 
skills and knowledge about medications, 
side effects, interactions and modes of 
administration. 
Framework
The evaluation of the protocol reported 
in this paper was designed with 
reference to a recognised framework 
for the development and evaluation of 
complex interventions.8 This framework 
requires preliminary attention to 
specific details including the scope to 
recruit patients and collect data in the 
primary care setting.9 In the primary care 
setting interventions often involve the 
interaction of multiple stakeholders and 
require co-operation across a variety of 
disciplines.10 There is an established case 
for development work and integration 
of process and outcome evaluation.11,12 
We aim to explore whether pharmacists’ 
involvement in palliative care could be 
facilitated through a modified process 
of ‘home medication review’. This study 
set out to field test a protocol that 
requires involvement of a nurse, doctor 
and a researcher to coordinate the 
Medication Management Review (MMR) 
by pharmacists.
A recent paper suggests that three factors 
be taken into account in the planning 
of the implementation of innovation in 
primary health care: 
1. staff expectations 
2. assessment of the perceived need for 
the innovation to be implemented, and 
3. its potential compatibility with existing 
routines.13 
Although it is clear that there is scope 
for the pharmacist to be involved with 
palliative care patients, the current 
system of care requires modification. 
Firstly patients in palliative care are not 
identified to the pharmacist unless (s)
he can work out that the patient is 
terminally ill from their list of prescribed 
medications. Secondly, the pharmacist 
will require further training in palliative 
care, and thirdly, there is no scope to 
remunerate practitioners for opportunity 
cost in offering advice without 
formally commissioning a medication 
management review. In developing the 
protocol for the medication management 
reviews several assumptions were made:
1. Medical practitioners have unknown 
opinions about the role of pharmacists 
in palliative care and cannot be 
assumed to be keen on ordering a 
medication management review in 
these circumstances.
2. The process of requesting an MMR 
involves the filling of forms that may be 
a hindrance to medical practitioners.14
3. Pharmacists may require additional 
support when conducting MMRs in 
what is considered a specialist area.
4. Accredited pharmacists who are 
registered to conduct an MMR are 
geographically dispersed and their 
input would need to be coordinated.
Methodology
The project was approved by WA Country 
Health Service (Board) Research Ethics 
Committee (WACHSBREC), the Curtin 
Human Health Research Ethics Committee 
and the Silver Chain Research Ethics 
Committee.
Setting and recruitment
Participants were palliative care clients of 
a community-based palliative care service 
in metropolitan Perth who were resident 
at home at the time of the study and 
deemed to be within six months of end of 
life. Patients were excluded if they were 
within days of death or were considered 
to have a cognitive impairment. Over 
a period of four months palliative care 
nurses recruited eligible patients and 
completed a palliative care MMR (PCMMR) 
referral form which was subsequently 
endorsed by the primary doctor (i.e. the 
palliative care general practitioner [GP] 
or the patient’s GP or family physician). 
Eligible patients were: 
1. receiving palliative care
2. using five or more medications, and 
3. able to give informed consent to 
participate. 
Figure 1 illustrates the procedure. A copy 
of the referral and a request for basic 
medication records (e.g. prescription 
history) were sent to the primary doctor 
and their community pharmacist. The 18 
accredited pharmacists who participated 
in the trial completed a two-day course 
on palliative care in the weeks before 
participating in the study. The course 
was presented by local experts and 
included the philosophy of palliative 
care, communications skills, symptom 
management and medications used in 
palliative care. Case studies and role plays 
with actors were used. The accredited 
pharmacists also had access to an 
experienced palliative care pharmacist as 
their mentor and access to members of 
the research team. Patients’ allocation to 
an accredited pharmacist was based on 
their area of residence and the nearest 
available accredited pharmacist. The 
accredited pharmacist conducted the 
PCMMR at the patient’s home. 
The accredited pharmacist prepared 
a report detailing their findings and 
recommendations, and forwarded the 
report to the project manager who 
then sent a copy to the referring GP. 
The accredited pharmacists were also 
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invited to keep a formal diary of ongoing 
contact with each patient for a follow-up 
period of between four weeks and three 
months after the PCMMR. The pharmacist 
documented the reason for each contact 
and their recommendations. 
Pharmacists’ recommendations
Five experts on the project team (two GPs 
and three pharmacists – including two 
university-based academic tutors and 
a specialist palliative care pharmacist) 
rated the clinical significance of each 
recommendation in the reports and 
the overall clinical significance of the 
report, based on a seven-point scale 
ranging from -3 (negative – not useful 
) to 3 (positive – useful). A final rating 
was calculated for each report and each 
recommendation by taking the mean of 
the experts’ ratings for each part. 
Patient evaluation of the PCMMR
A form was generated for patients’ 
evaluations of the medication reviews; 
it had two parts. First, the patients were 
presented with seven statements about 
the medication review. For example, one 
statement read, ‘I feel more comfortable 
about taking my medications’. For each 
statement the patient rated how much 
he or she agreed (or disagreed) using 
a 5-point Likert scale ranging from 1 – 
‘strongly disagree’ to 5 – ‘strongly agree’, 
where 3 was ‘neutral.’ In the second part 
of the evaluation, patients were asked to 
provide comments about the review.
Results
PCMMR completions
The project manager received a total of 
48 PCMMR referrals. Patients were aged 
between 8 years and 85 years (M = 65.7 
years, SD = 14.5) and were experiencing 
up to seven common palliative care 
symptoms at the time of referral. Three 
patients died before their PCMMR could 
be scheduled, two patients withdrew 
from the study before their review due 
to a deterioration in their health, and a 
further two patients withdrew before 
their review without stating a reason. 
Another referral did not provide sufficient 
information, leaving a total sample of 40 
patients who completed the study. Of 
the 18 eligible accredited pharmacists, 13 
conducted PCMMRs. The 13 pharmacists 
each conducted between one and nine 
reviews (M = 3.1, SD = 2.3) and made a 
total of 145 recommendations. The trial 
was designed to ensure rapid delivery of 
the PCMMR service. However, between 
two and 30 days elapsed from when 
the patient signed the referral consent 
form, to when the pharmacist’s report 
was provided to the referring GP (M 
= 10.6 days, SD = 6.0). Some reviews 
were delayed because the patient’s 
health deteriorated or the review was 
conducted after the need for advice 
had lapsed; other reasons were delays 
in the administrative process, limited 
endorsement of the referral process 
by GPs, inadequate information 
provided in the referral form (including 
a telephone contact number for 
the patient), and by delays due to 
the unavailability of a nurse at the 
recruiting site.
Pharmacists’ recommendations
The pharmacists provided between nil 
and nine recommendations per patient 
in their reports to the doctor. In total, 
there were 145 recommendations. The 
majority (93%) of the ratings for the 
overall reports were positive, 4% were 
negative and 3% were rated as neutral. 
The mean ratings for the individual 
recommendations ranged between -1.0 
to 2.7 (mean = 1.2, standard deviation = 
0.69). The majority of the mean ratings 
(95%) were positive; two (1%) were 
negative and six (4%) were neutral. 
The combined ratings of the reports 
were typically positive; however there 
was a lack of consensus on the value of 
individual recommendations between 
the raters.
Patient evaluations
In total, 25 evaluations were returned 
(of 48, 52%). Table 1 shows the patients’ 
responses to each of the seven 
statements. In short, the patients 
were generally very positive about 
the medication review with the mean 
responses falling between ‘agree’ and 
‘strongly agree’ on the rating scale.
The small ranges for statement 2, 
statement 6 and statement 7 highlight 
that all patients felt comfortable talking 
to the pharmacist, able to ask questions 
of the pharmacist and willing to contact 
the pharmacist in the future if need 
be. For the remaining statements, 
some of the lower responses came 
with comments emphasising that 
Figure 1. Steps in the protocol for the PCMMR feasibility study. 
Nurse recruits participant
Nurse completes MMR  
request form
MMR request endorsed by GP
Pharmacist continues to keep 
log of patient contacts for at 
least 4 weeks after MMR
Form relayed to  
project manager
GP responds to report 
with or without changes 
to prescriptions
Form relayed to 
accredited pharmacist 
Accredited pharmacist 
conducts review and sends 
to project manager who then 
sends it to the GP
(GP= General practitioner)
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people felt they already understood their 
medications; these ratings may have been 
more a reflection that some patients were 
already very well informed rather than 
a reflection of unsatisfactory input from 
the pharmacist. 
The final question on the evaluation 
asked patients whether they had any 
comments about the review. Of the 
25 responses received, 18 provided 
comments (72%). The comments were 





4. providing information, or 
5. making a suggestion for improvement. 
In total, 15 comments (83%) were coded 
as positive. For example, one comment 
read, ‘It was very comforting to have 
someone actually sit down with me and 
go through my meds.’ One comment 
was coded as providing information, 
as it simply provided a description of 
the outcome of the review and doctor’s 
subsequent intervention. One comment 
was a suggestion, ‘It would have been 
helpful to receive a post meeting letter 
reviewing the meeting and advising of 
further steps/options.’ The final comment 
was coded as neutral. This comment 
read, ‘We don’t have any issues with our 
medications. We have been on the same 
ones for 15 months. We know if we have a 
problem we can contact a pharmacist.’
In summary, the medication reviews 
generally seemed to be a positive 
experience for patients and, for the 
vast majority, left patients feeling more 
informed and better able to manage their 
medications. 
Pharmacists’ interaction records 
Only three pharmacists formally recorded 
their patient interactions post PCMMR; 
with most reporting that they did not 
use the diaries. A total of 17 patient 
interactions involving 13 patients were 
reported during the follow-up period. 
Eight interactions were initiated by the 
accredited pharmacists (47%), seven 
were by GPs and two by carers. The 
contact was used mainly for sharing or 
requesting information, however two 
of the interactions resulted in a change 
in medication. We cannot confirm from 
these data that patients did not contact 
their pharmacist in the follow up stage 
because of the lack of compliance with 
the diary keeping by the majority of 
pharmacists.
Discussion
The protocol to formally involve 
pharmacists in the care of patients in 
palliative care in a community setting 
had limited success. The process of 
ordering the review involved the patient, 
a nurse, a doctor and a project manager. 
The delays in conducting the reviews, 
in some cases up to 30 days from the 
patient requesting a review, suggest that 
each step introduced further risk of delay 
to the process. There were a number of 
practical problems including the speed 
of the review and the amount of relevant 
information passed to the pharmacist.
The Promoting Action on Research 
Implementation in Health Services 
(PARIHS) framework suggests that 
implementation success is a function 
of the nature and type of evidence, the 
qualities of the context, and the way 
the process is facilitated.15 The flow of 
relevant and timely information was a 
major shortcoming in this study. A key 
issue was the need for more efficient relay 
of relevant information. 
An important factor in designing 
strategies for new models of health care 
is how to obtain behavioural change 
among health care providers. Rogers 
describes behavioural change as an 
innovation-decision process that leads 
either to adoption (i.e. to make full use 
of an innovation) or rejection (i.e. not 
to adopt). This process occurs on an 
organisational level and on an individual 
level.16 It was clear in this study that 
both individuals and organisations had 
the scope to moderate the potential for 
patients to benefit from engagement 
of pharmacists in palliative care. In this 
case we recommend greater dialogue 
between the representative bodies 
representing the stakeholder groups. 
Within general practice this includes 
the practices and their representative 
body, including the Divisions of General 
Practice, and in pharmacy this includes 
the pharmacies and their peak bodies. A 
review of the literature suggests that the 
primary role for community pharmacists 
in palliative care is the safe administration 
of medication and to act as a source of 
advice for patients. With appropriate 
arrangements, pharmacist can also 
deliver a service to the patient’s home, 
and enable those in the terminal phase 
to remain at home for as long as it is 
practical.17 Systems need to be developed 
so that community pharmacies have the 
mechanisms to work in close consultation 
with the medical and nursing team 
caring for the patient. Pain and symptom 
management are also central issues in 
palliative care; frequently nurses consult 
with distressed patients and family 
members about pain management. When 
they do so they act simultaneously to 
relieve pain but also counsel distressed 
people.18 The multi-faceted nature of 
palliative care requires professionals 
working with terminal patients to 
have a greater capacity for empathy, 
the ability to address psychosocial 
Table 1. Patients’ ratings of evaluation statements
Statement Mean (SD) Range
1. The pharmacist provided me with information about my 
medications.
4.36 (0.86) 1 – 5
2. I was able to ask the pharmacist questions about my 
medications.
4.72 (0.46) 4 – 5 
3. The pharmacist helped me to understand my medications 
better.
4.36 (0.91) 1 – 5 
4. I feel more able to manage my medications. 4.20 (0.87) 1 – 5 
5. I feel more comfortable taking my medications. 4.16 (1.03) 1 – 5 
6. I felt comfortable talking to the pharmacist. 4.80 (0.41) 4 – 5 
7. I would contact the pharmacist again to ask questions about 
my medication if I needed to. 
4.64 (0.49) 4 – 5 
RESEARCH
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needs, a sophisticated knowledge 
of medical ethics, and excellence in 
communication skills.18 These issues 
were extensively reviewed in the full 
report on this project.19 Although 
many of these skills are addressed in 
medical and pharmaceutical training, 
research indicates that many health care 
professionals are poorly prepared for 
the complexities of palliative care.
Exemplary health systems assimilate 
the input of physicians, pharmacists, 
nurses and psychosocial carers in a 
holistic framework and foster increased 
confidence in delivering excellent 
palliative care.20 At the same time it 
is important to acknowledge that in 
Australia the fee for service model 
of care that is an integral part of the 
primary care service is extended to 
include all members of the team. To 
facilitate the PCMMR it may also be that 
the process would be better supported 
if both nurses and GPs were able to 
claim a fee for making the referral.7 
This is not currently permitted under 
the rules.
In addition, there needs to be a 
mechanism for actively encouraging 
referrals and closer collaboration 
among palliative care doctors, GPs 
and accredited pharmacists. There was 
limited evidence for this in our study. 
This might be expected given the short 
duration of the study; collaboration is 
built on a shared understanding which 
may develop over time. There is also 
a need for accredited pharmacists to 
be formally inducted as members of a 
multidisciplinary palliative care team.20
Conclusion
Overall pharmacists are capable of 
providing this service and, with training 
and further support, implementation of 
this service is viable. Patients have found 
this service beneficial. However the study 
identified a number of problems with the 
protocol used; some were unique to the 
delivery of the PCMMR service and others 
are generic to medication management 
review models operating in Australia. There 
needs to be support at the organisational 
and policy levels to ensure that the process 
is simple and efficient, and also at the 
individual level to nurture collaboration 
between all health professionals involved in 
care at the end of life.
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Shock-absorbing, anti-slip Flexyfoot 
replaces the old fashioned ferrule (or 
rubber tip) on walking sticks, crutches 
and other aids such as walking frames 
and shower stools. According to 
Flexyfoot Australia Flexyfoot gives 
50% more grip on floors and ground 
surfaces than conventional ferrules 
and eases aches and pains associated 
with repeated stress and impact 
forces on upper limb joints, which are 
not attenuated by ferrules. It claims 
that with its patented air sprung 
technology, Flexyfoot bends and can 
rotate 360 degrees, which allows users 
to easily turn on their walking aids and 
reduces twisting forces on the wrist. It 
is designed to help people of all ages 
and levels of fitness: sports people, 
the elderly, children and people with 
a disability, for both temporary and 
permanent requirements.
Invented by British designer, David 
Goodwin, Flexyfoot was developed 
over three years, trialled with a leading 
orthopaedic surgeon and physiotherapy 
department and tested exhaustively to 
surpass standards. Brothers Geoff and 
Tim Pryde have established Flexyfoot 
Australia and will exclusively distribute 
the full range of Flexyfoot nationally. It 
comes in four sizes and two heights to 
meet different user requirements. Geoff 
Pryde, a musculoskeletal physiotherapist 
said, ‘Flexyfoot offers a high quality 
product that looks great and will fit most 
walking sticks and crutches. It offers our 
clients a superior experience of walking 
aid use, whether they are an injured 
footballer who needs a walking aid to 
negotiate various surfaces, or an elderly 
person looking for a simple way to make 
their walking aid feel more secure’.
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